6ILQ image
Deposition Date 2018-10-19
Release Date 2019-09-11
Last Version Date 2023-11-22
Entry Detail
PDB ID:
6ILQ
Keywords:
Title:
Crystal structure of PPARgamma with compound BR101549
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.41 Å
R-Value Free:
0.30
R-Value Work:
0.21
R-Value Observed:
0.22
Space Group:
C 2 2 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Peroxisome proliferator-activated receptor gamma
Gene (Uniprot):PPARG
Chain IDs:A
Chain Length:272
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:Nuclear receptor coactivator 1
Gene (Uniprot):NCOA1
Chain IDs:B
Chain Length:25
Number of Molecules:1
Biological Source:Homo sapiens
Ligand Molecules
Primary Citation
Identification of BR101549 as a lead candidate of non-TZD PPAR gamma agonist for the treatment of type 2 diabetes: Proof-of-concept evaluation and SAR.
Bioorg.Med.Chem.Lett. 29 631 637 (2019)
PMID: 30594432 DOI: 10.1016/j.bmcl.2018.12.043

Abstact

The new class of PPARgamma non-TZD agonist originally derived from the backbone of anti-hypertensive Fimasartan, BR101549, was identified as a potential lead for anti-diabetic drug development. The X-ray crystallography of BR101549 with PPARgamma ligand binding domain (LBD) revealed unique binding characteristics versus traditional TZD full agonists. The lead candidate, BR101549, has been found activating PPARgamma to the level of Pioglitazone in vitro and indeed has demonstrated its effects on blood glucose control in mouse proof-of-concept evaluation. The attempts to improve its metabolic stability profile through follow-up SAR including deuterium incorporation have been also described.

Legend

Protein

Chemical

Disease

Primary Citation of related structures